THE ROLE OF HEPCIDIN 25 IN THE DEVELOPMENT OF ANEMIC SYNDROME ASSOCIATED WITH MALIGNANT DISEASES

Anemic syndrome (АС) is a frequent complication of cancer that gives poor results of treatment and reduces quality of live of patients. The literature review is devoted to the role of the peptide hormone hepcidin 25 (HP25), which regulates systemic and local iron homeostasis, in the development of anemia. The main biological function of HP25 is to reduce the level of iron in the bloodstream, which realizes a decrease of the mobilization of iron from the depot and a decrease of absorption of iron in the intestine. Modern approaches to the diagnosis and treatment of anemic disease in oncological practise necessarily include an assessment of the level of HP25. It was shown that HP25 is involved in the pathogenesis of anemia in malignant neoplasms. Oncological diseases are often accompanied by high levels of pro-inflammatory cytokines, in particular interleukin-6 (IL-6), which causes an increase in the production of HP25. Under the influence of IL-6, HP25 blocks ferroportins and iron release by macrophages, which leads to the development of functional iron deficiency and iron deficiency erythropoiesis, thus, with prolonged exposure to pro-inflammatory cytokines, anemia of chronic disease develops. The treatment of АС associated with malignant neoplasms is a complex procedure. Therapeutic effect on HP25 and IL-6 is a promising prospect for the correction of anemia in cancer patients. New strategies in the pathogenetic therapy of patients with anemia are associated with the use of antihepcidin drugs that reduce the level of HP25 in the blood. However, some studies have shown that an increase in the iron content in the bloodstream increases its accessibility to the tumor and promotes its growth; therefore, further, more in-depth study of the problem of correcting АС in cancer patients is necessary

cancer patients, anemia, interleukin-6, hepcidin 25

1. Knight K., Wade S., Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116(Suppl 7A):11S–26S. DOI: 10.1016/j.amjmed.2003.12.008.

2. Aapro M., Beguin Y., Bokemeyer C. et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2018;29(Suppl 4):iv96–iv110. DOI: 10.1093/annonc/mdx758.

3. Nicolae C.D., Coman O.A., Ene C. et al. Hepcidin in neoplastic disease. J Med Life 2013;6(3):355–60. PMID: 24146699.

4. Chaparro C.M., Suchdev P.S. Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. Ann N Y Acad Sci 2019;1450(1):15–31. DOI: 10.1111/nyas.14092.

5. Blindar V.N., Zubrikhina G.N., Davydova T.V. et al. The development of the strategic approaches to modern diagnosis of anemic syndrome in patients with breast cancer. Klinicheskaya laboratornaya diagnostica = Russian Clinical Laboratory Diagnostics 2019;64(4):210–5. (In Russ.).

6. Krause A., Neitz S., Magert H.J. et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480(2–3):147– 50. DOI: 10.1016/s0014-5793(00)01920-7.

7. Park C.H., Valore E.V., Waring A.J. et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276(11):7806–10. DOI: 10.1074/jbc.M008922200.

8. Pigeon C., Ilyin G., Courselaud B. et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276(11):7811–9. DOI: 10.1074/jbc.M008923200.

9. Haase V.H. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol 2010;299(1):1–13. DOI: 10.1152/ajprenal.00174.2010.

10. Tesfay L., Clausen K.A., Kim J.W. et al. Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res 2015;75:2254–63. DOI: 10.1158/0008-5472.CAN-14-2465.

11. Pippard M.J., Callender S.T., Warner G.T. et al. Iron absorption and loading in beta-thalassaemia intermedia. Lancet 1979;2(8147):819–21.

12. Iolascon A., Esposito M.R., Russo R. Clinical aspects and pathogenesis of congenital dyserythropoietic anemias: from morphology to molecular approach. Haematologica 2012;97(12):1786–94. DOI: 10.3324/haematol.2012.072207.

13. Pootrakul P., Sirankapracha P., Hemsorach S. et al. A correlationof erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patients with thalassemia. Blood 2000;96(7):2606–12.

14. Tanno T., Bhanu N.V., Oneal P.A. et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13(9): 1096–101. DOI: 10.1038/nm1629.

15. Kautz L., Jung G., Valore E.V. et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014;46(7):678–84. DOI: 10.1038/ng.2996.

16. Origa R., Galanello R., Ganz T. et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007;92(5):583–8. DOI: 10.3324/haematol.10842.

17. Roy C.N. Anemia of inflammation. Hematol Am Soc Hematol Educ Program 2010;2010:276–80. DOI: 10.1182/asheducation-2010.1.276.

18. Chung A., Leo K., Wong G. et al. Giant hepatocellular adenoma presenting with chronic iron deficiency anemia. Am J Gastroenterol 2006;101(9):2160–2. DOI: 10.1111/j.1572-0241.2006.00607.x.

19. Finberg K.E., Heeney M.M., Campagna D.R. et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008;40(5): 569–71. DOI: 10.1038/ng.130.

20. Sasu B.J., Cooke, K.S., Arvedson T.L. et al. Antihepcidin antibody treatment modulates iron metabolism and effective in a mouse model of inflammationinduced anemia. Blood 2010;115(17):3616–24. DOI: 10.1182/blood-2009-09-245977.

21. Hong D.S., Angelo L.S., Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007;110(9):1911–28. DOI: 10.1002/cncr.22999.

22. Maccio A., Madeddu C., Massa D. et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 2005;106(1):362–7. DOI: 10.1182/blood-2005-01-0160.

23. Nieken J., Mulder N.H., Buter J. et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 1995;86(3):900–5.

24. Nemeth E., Rivera S., Gabajan V. et al. IL-6 mediates hypo-ferramia inducing synthesis of the iron regulatory hormone hepcidin. J Clin Inv 2004;113(9):1271–6. DOI: 10.1172/JCI20945.

25. Noguchi-Sasaki M., Sasaki Y., Shimonaka Y. et al. Treatment with antiIL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells. BMC Cancer 2016;16:270. DOI: 10.1186/s12885-016-2305-2.

26. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002;420:860–7. DOI: 10.1038/nature01322.

27. Sasu B.J., Cooke K.S., Arvedson T.L. et al. Antihepcidin antibody treatment modulates iron metabolism and effective in a mouse model of inflammation-induced anemia. Blood 2010;115(17):3616–24. DOI: 10.1182/blood-2009-09-245977.

28. Vadhan-Raj S., Abonour R., Goldman J.W. et al. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. Journal of Hematology Oncology 2017;10(73):1–12. DOI: 10.1186/s13045-017-0427-x.

29. Kurzrock R., Voorhees P.M., Casper C. et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell nonHodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013;19(13):3659–70. DOI: 10.1158/1078-0432.CCR-12-3349.

30. Pinnix Z.K., Miller L.D., Wang W. et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010;2(43):43ra56. DOI: 10.1126/scisignal.3001127.

31. Zhang S., Chen Y., Guo W. et al. Disordered hepcidin-ferroportin signaling promotes breast cancer growth. Cell Signal 2014;26(11):2539–50. DOI: 10.1016/j.cellsig.2014.07.029.